Professor John Camm is an internationally renowned expert in atrial fibrillation.
Professor Camm’s research centres on atrial fibrillation (AF), ventricular tachycardia, ventricular fibrillation, sudden cardiac death, cardiac channelopathy, cardiovascular safety of drugs, acquired long QT syndrome and risk stratification for serious outcome events.
He leads the European Network for translational research in atrial fibrillation (EUTRAF). This a collaboration of academic centres and industrial partners from across Europe, working together to generate a better understanding of the causes and mechanism of AF, the most common type of irregular heartbeat, affecting four to five million people in Europe. Funded by the European Union 7th Framework Programme for five years, EUTRAF aims to develop better diagnostic tools and treatment for AF.
Professor Camm's projects include clinical trials of novel oral anticoagulants for AF and ventricular arrhythmias; antiarrhythmic agents, visualisation, imaging and ablation of atrial ganglionic plexuses; atrial defibrillation with novel waveforms for implantable devices; and body surface mapping of AF using high density body ECG electrode arrays.
He sits on the steering committees of number of international clinical trials, including the HARMONY trial, evaluating a fixed-dose combination of ranolazine and dronedarone for AF and the EAST trial, evaluating early rhythm control therapy in AF.
Professor Camm chairs the Data and Safety Monitoring Board of CASTLE-AF, a trial evaluating the effectiveness of catheter-based radio-frequency ablation of AF compared to conventional treatment in patients with heart failure. He is a member of similar committees for six other ongoing clinical trials.
Professor Camm trained at Guy's Hospital, London and pursued a career in cardiology at St Bartholomew's Hospital until 1986 when he became British Heart Foundation chair of clinical cardiology at St George's and honorary consultant cardiologist at St George’s University Hospitals NHS Foundation Trust.
Professor Camm holds the European Society of Cardiology Gold Medal (awarded 2005), given to 'exceptional cardiologists for their contribution to medicine' and the British Cardiovascular Society Mackenzie Medal (awarded 2008), given annually for 'outstanding service to British cardiology.'
He sits on the boards of the European Heart Rhythm Association, the World Society of Arrhythmias , and the Drug Safety Research Trust (the Trust's operational arm is the Drug Safety Research Unit that studies and monitors the safety of medicines).
In the UK, he is president of the Arrhythmia Alliance, a coalition of charities, patient groups, patients, carers, doctors and other professionals who work together to 'promote timely and effective diagnosis and treatment of arrhythmias'. He is also founder and trustee of the Atrial Fibrillation Association.
He is editor-in-chief of Clinical Cardiology and EP-Europace, and an editor of the European Heart Journal and the European Society of Cardiology Textbook of Cardiovascular Medicine.
Professor Camm has been involved in the production of numerous clinical guidelines. For example, he chaired the committee responsible for producing the European Society of Cardiology Guidelines for the management of atrial fibrillation, first published in 2010, and updated (with the European Hearth Rhythm Association) in 2012.
And he led the production of 2010 guidelines for England and Wales from the National Institute for Health and Care Excellence (NICE) about the treatment of unstable angina and NSTEMI (non-ST-segment-elevation myocardial infarction – a type of heart attack).
In the past, Professor Camm has been chair of the European Society of Cardiology Working Group on Cardiac Arrhythmias (now European Heart Rhythm Association), president of the British Pacing and Electrophysiology Group (now Heart Rhythm UK), council member of the Royal College of Physicians, trustee of the North American Society of Pacing and Electrophysiology (now Heart Rhythm Society) and trustee of the American College of Cardiology.
Professor Camm is also a former chairman of the Joint Cardiology Committee (Royal College of Physicians of London) and past president of the British Cardiovascular Society.
Hohnloser SH, Camm AJ. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. Europace. 2013, Aug 16, Epub ahead of print.
Katritsis DG, Pokushalov E, Romanov A, Giazitzoglou E, Siontis GC, Po SS, Camm AJ, Ioannidis JP. Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fibrillation: a randomised clinical trial. J Am Coll Cardiol. 2013, Aug 8, Epub ahead of print.
Curtis MJ, Hancox JC, Farkas A, Wainwright CL, Stables CL, Saint DA, Clements-Jewery H, Lambiase PD, Billman GE, Janse MJ, Pugsley MK, Ng GA, Roden DM, Camm AJ, Walker MJ. The Lambeth Conventions (II): guidelines for the study of animal and human ventricular and supraventricular arrhythmias. Pharmacol Ther. 2013, Aug;139 (2): 213-48.
Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013 May; 15(5): 625-51.
Boos CJ, Nam M, Camm AJ. Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure. Heart Fail Rev. 2013, June 25. Epub ahead of print.
Torp-Pedersen C, Camm AJ, Butterfield NN, Dickinson G, Beatch GN. Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease. Int J Cardiol. 2013, June 5; 166(1): 147-51.
Garratt CJ, Griffith MJ, Young G, Curzen N, Brecker S, Rickards AF, Camm AJ. Value of physical signs in the diagnosis of ventricular tachycardia. Circulation. 1994, Dec; 90(6): 3103-7.
Saumarez RC, Camm AJ, Panagos A, Gill JS, Stewart JT, de Belder MA, Simpson IA, McKenna WJ. Ventricular fibrillation in hypertrophic cardiomyopathy is associated with increased fractionation of paced right ventricular electrograms. Circulation. 1992, Aug; 86(2): 467-74.
Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet. 1997, Mar 8; 349(9053): 667-74. Erratum in: Lancet, 1997, Jun 14;349(9067):1776 and Lancet ,1997, Apr 19; 349(9059): 1180.
Within the Cardiovascular Sciences Research Centre, Professor Camm works with a number of colleagues:
Professor Marek Malik, professor of cardiac electrophysiology (risk stratification);
Dr Elijah Behr, senior lecturer (inherited cardiac arrhythmias);
Dr Ayesha De Souza, senior research fellow (atrial fibrillation); and Dr Irina Savelieva (atrial fibrillation).
As coordinator of the European Network for translational research in atrial fibrillation (EUTRAF), Professor Camm collaborates with specialist investigators in the field working at academic centres and industrial partners across Europe. For a full list of partners, visit the EUTRAF website.
The European Network for translational research in atrial fibrillation (EUTRAF).
Awarded to St George's, University of London (AJ Camm – project coordinator) and 19 other organisations.
European Union 7th Framework Programme.
2010 to 2015, €15 million (including €12 million from European Commission).
Professor Camm teaches junior doctors in his capacity as consultant cardiologist at St George’s University Hospitals NHS Foundation Trust.